Differential expression of SHP-1 in chronic myeloid leukemia
暂无分享,去创建一个
B. Dörken | K. Mills | M. Schwarz | I. Zalcberg | J. Kaeda | P. le Coutre | F. Ringel | S. Bonecker | A. Serra | L. Amini | D. Neuman | Christian Oberender
[1] M. Caligiuri,et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.
[2] H. Kantarjian,et al. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. , 2013, Clinical lymphoma, myeloma & leukemia.
[3] Catriona H. M. Jamieson,et al. Chronic Myeloid Leukemia Stem Cell Biology , 2012, Current Hematologic Malignancy Reports.
[4] J. Radich,et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. , 2011, Blood.
[5] G. Garcia-Manero,et al. Decreased expression level of SH2 domain‐containing protein tyrosine phosphatase‐1 (Shp1) is associated with progression of chronic myeloid leukaemia , 2007, The Journal of pathology.
[6] D. Marin,et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. , 2006, Blood.
[7] Guido Marcucci,et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.
[8] Susan Branford,et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.
[9] U. Lorenz,et al. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation , 2001, Leukemia.